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Abstract: Cyclooxygenase-2 (COX-2), the prostaglandin (PG)-synthesizing enzyme 
overexpressed in colorectal cancer (CRC), has pleiotropic, cancer-promoting effects. COX-2 
inhibitors (CIBs) interfere with many cancer-associated processes and show promising anti-
neoplastic activity, however, a common mechanism of CIB action has not yet been established. 
We therefore investigated by microarray the global response towards the CIB APHS at a dose 
signiﬁ  cantly inhibiting the growth of three COX-2-positive CRC but not of two COX-2-negative 
cell lines. None of the genes signiﬁ  cantly (p = 0.005) affected by APHS were common to all 
three cell lines and 83% of the altered pathways were cell line-speciﬁ  c. Quantitative polymerase 
chain reaction (QPCR) on selected pathways conﬁ  rmed cell line-speciﬁ  c expression alterations 
induced by APHS. A low stringency data analysis approach using BRB array tools coupled 
with QPCR, however, identiﬁ  ed small expression changes shared by all COX-2-positive cell 
lines in genes related to the WNT pathway, the key driver of colonic carcinogenesis. Our data 
indicates a substantial cell line-speciﬁ  city of APHS-induced expression alterations in CRC cells 
and helps to explain the divergent effects reported for CIBs. Further, the shared inhibition of the 
WNT pathway by APHS suggests one potential common mechanism behind the antineoplastic 
effects of COX-2 inhibition.
Keywords: antineoplastic drugs, cell lines, colon cancer, COX-2 inhibitors, DNA arrays, 
WNT factors
Introduction
A large body of evidence from various disciplines indicates that common nonsteroidal 
anti-inﬂ  ammatory drugs (NSAIDs) have an impressive potency in the prevention of 
colorectal cancer (reviewed in Brown and DuBois 2005). The antineoplastic activity 
of NSAIDs has been attributed to their ability to inhibit the prostaglandin synthases, 
particularly cyclooxygenase-2 (COX-2), which is overexpressed in and responsible 
for the high levels of prostaglandins (PGs) such as PGE2 in colorectal cancer (CRC). 
PGs bind to speciﬁ  c receptors, thereby inducing pleiotropic effects on processes such 
as proliferation, apoptosis, differentiation, migration, angiogenesis, and immunosup-
pression (Brown and DuBois 2005). Despite numerous studies, however, no pathway 
downstream of the PG receptors has been described to date that is consistently affected 
by NSAIDs. Possible explanations for this apparent mechanistic heterogeneity include 
cell line-, organism-, and drug-speciﬁ  c effects.
In this study, we aimed to estimate the level of heterogeneity with which different 
CRC cell lines react to inhibition of COX-2. We analyzed by microarray the expres-
sion response of CRC cells following treatment with an irreversible COX-2 inhibitor Biologics: Targets & Therapy 2008:2(2) 330
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(CIB) at a dose which speciﬁ  cally reduced colony formation 
of COX-2 expressing CRC cells. Based on conﬁ  rmation by 
quantitative polymerase chain reaction (QPCR), our results 
indicate that each cell line responds individually to COX-2 
inhibition. However, the observation that components of the 
WNT pathway were similarly affected in COX-2 expressing 
cells suggests potential common mechanisms underlying 
CIB action may exist.
Materials and methods
Cell lines and drug treatment
APHS (o-(acetoxyphenyl)hept-2-ynyl sulfide; Cayman 
Chemical, Ann Arbor, MI, USA) was dissolved in dimethyl 
sulfoxide (DMSO) under N2 at 100 mM and stored at −20 °C. 
SW480, SW620, CaCo-2, and HT-29 cells were from the 
American Type Culture Collection. HCA-7 was a kind gift 
from S.C. Kirkland (Kirkland 1985). Cells were grown in 
DMEM with 5% fetal bovine serum (FBS) at 5% CO2 with 
the addition of 0.01 mg/ml transferrin for CaCo-2 cells. 
Single cell suspensions were prepared by passage through 
a 0.4 mm needle. Cells were seeded at 200–400 cells/cm2, 
treated with APHS or vehicle 24 h later and left to form 
colonies for 7–10 days. DMSO (vehicle) concentration was 
kept below 1% in all experiments. Colonies were stained with 
1% Crystal Violet, photographed and total cellular area was 
measured using National Institutes of Health (NIH) Image 
software (http://rsb.info.nih.gov/nih-image/).
Microarray analysis
For microarray analysis, cells were seeded at 5800 cells/cm2 
and treated with 40 μM APHS or 0.4% DMSO 24 h later 
(before colony growth onset). Total RNA was isolated 48 h 
following treatment. Initial pilot experiments suggested that 
at this time point, ﬁ  rst signiﬁ  cant expression changes induced 
by APHS were detectable. Sample and reference cDNAs 
(pooled samples of cells at 0 and 48 h after treatment with 
vehicle) were Cy3/Cy5-labeled and hybridized (40 μg) as 
duplicates to arrays duplicate-printed with the ‘6017 human 
cDNA clone set’ (Research Genetics). The procedure fol-
lowed the protocols developed by Dr. J. DeRisi, University of 
California, San Francisco (see http://www.microarrays.org). 
Feature selection was performed using GenePix 4.0 software 
(Axon Instruments, Inc, Foster City, CA, USA). Expression 
data were normalized using SNOMAD (Standardization and 
Normalization of MicroArray Data), which ﬁ  rst performs 
background subtraction to include only spots with intensities 
over background, then performs global mean normalization 
and local mean normalization across the array surface (Loess), 
followed by local mean normalization and local variance 
correction across the spot signal intensity (for details see 
http://pevsnerlab.kennedykrieger.org/snomadinput.html). 
Manual ﬁ  ltering was performed visually by ﬂ  agging out any 
irregular or faint spots and yielded 5429 quantiﬁ  able gene 
spots. For each gene, the APHS-induced expression change 
relative to DMSO treatment was calculated (ΔZ = ZAPHS-ZDMSO, 
where Z equals the normalized logarithmic standard deviation 
from the mean). ΔZ-gene lists were then searched for genes 
that were differentially expressed in coxP cell lines relative 
to the coxN cell lines to obtain genes speciﬁ  cally altered 
in cells responding to APHS with growth inhibition. The 
geometric ΔZ mean value of a gene from all coxP cells was 
compared to that of all coxN cells (BRB-ArrrayTool version 
3.3; developed by Dr. Richard Simon and Amy Peng Lam, 
http://linus.nci.nih.gov/~brb/, ‘class comparison’ using an 
unpaired t-test assuming unequal variance with p = 0.005, 
2000 permutations and Bonferroni-corrected for multiple 
testing). Similarly, ΔZ values from each individual coxP cell 
line were compared with the ΔZ mean of coxN cells to obtain 
cell-line speciﬁ  c gene expression changes.
To detect multiple gene expression changes that are part 
of a pathway (sets of interacting genes as deﬁ  ned by the Kegg 
and Biocarta pathway data bases), BRB-ArrayTools’ ‘path-
way comparison’ was used. In this test, a p-value based on a 
t-test is assigned to the ΔZ value of each gene of a given path-
way. The set of p-values is summarized by the non-parametric 
LS and KS summary statistics to test whether the p-values 
have a uniform distribution. By computing the empirical 
distributions of the summary statistics in random gene set 
samples derived from the total gene set, the hypothesis is 
tested whether the pathway gene set contains more genes 
differentially expressed between the classes compared than 
would be expected by chance (at a signiﬁ  cance level 0.005 
and 105 permutations). Thus, a differentially expressed path-
way can consist of genes that are not signiﬁ  cantly altered at 
the single gene level (t-test p  0.005), however, the distri-
bution of their alterations is non-random. Using this test, we 
compared ΔZ values of each individual coxP cell line with 
the ΔZ mean of the coxN cells to detect cell line-speciﬁ  c, 
differentially expressed pathways. To detect very small 
changes in pathway gene sets, we combined the coxP cells 
and compared their mean ΔZ values with that of the coxN 
cells. The RARA pathway was detected using PathwayAssist 
(Iobion) which searches interactions reported in the literature 
rather than screening public data bases. The colonic dif-
ferentiation cluster was created by selecting genes linked to 
the term ‘colon epithelium differentiation’ using PubMatrix Biologics: Targets & Therapy 2008:2(2) 331
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(see http://pubmatrix.grc.nia.nih.gov/secure-bin/index.pl) 
from a list of genes that were contained in the 6K cDNA set 
and assigned the ontology term ‘differentiation’.
Quantitative real-time PCR
Based on the microarray pathway analysis, genes that repre-
sented a given pathway (upstream, central, and downstream 
relative to a pathway) were selected for conﬁ  rmation by QPCR 
performed on the cDNA samples as used for microarray. 
Primers and probes for all genes were purchased as Assay-
OnDemand (AppliedBiosystems, Victoria, Australia), with 
the exception of the primers/probes for COX2 and the control 
ACTB (β-actin), which are described by Humar and colleagues 
(2001). The cycle numbers (Ct) of analyzed genes were below 
36. Relative expression was expressed as 2-ΔCt, with ΔCt = Ctgene 
– Ctactin. SD was determined from triplicate measurements of 
ΔCt values. SD of relative expression was estimated as SDrel 
= (2-(ΔCt-SD) – 2-(ΔCt + SD))/2 (Humar et al 2001).
Results
In order to investigate whether different CRC cell lines dis-
play a heterogeneous response towards inhibition of COX-2 
or whether their response includes common components, we 
used microarrays to obtain global expression proﬁ  les follow-
ing growth inhibition of CRC cells by the irreversible CIB 
APHS (Kalgutkar et al 1998).
The effects of APHS were assessed using colony forma-
tion assays on the following ﬁ  ve cell lines: HCA-7, CaCo-2, 
HT-29 (coxP: positive for COX2 expression as assessed by 
QPCR; not shown), SW480 and its metastatic derivative 
SW620 (coxN: negative for COX2 expression). The APHS 
concentration required to inhibit colony formation by 50% 
(IC50) compared to vehicle-treated controls was 14 μM for 
HT-29, 37 μM for CaCo-2, 48 μM for HCA-7, 67 μM for 
SW620, and 78 μM for SW480 cells (Figure 1A). The lower 
IC50 of APHS for coxP cells is likely due to COX-2 inhibition, 
as (i) APHS blocks COX-2 15x stronger than COX-1, and 
(ii) COX-1 expression in the cell lines measured by QPCR 
did not correlate with the APHS effects (not shown).
Based on the dose-response experiments, 40 μM APHS 
was chosen and inhibited the growth of coxP cell lines at 
least 50% whilst having little effect on coxN CRC cells. This 
APHS dose induced a similar response in colony formation 
assays where cells were seeded at a density sufﬁ  ciently high 
to extract RNA for array hybridization (Figure 1B).
Forty-eight hours after treatment with APHS or vehicle, 
RNA was isolated to generate expression proﬁ  les using 
cDNA arrays. Unsupervised hierarchical clustering of the 
proﬁ  les revealed co-clustering of sample duplicates. Further, 
APHS- and vehicle-treated samples of coxN cells clustered 
together. In contrast, APHS-treated samples of coxP cells 
clustered away from vehicle-treated samples, indicating that 
40 μM APHS induced an expression response in coxP but 
not coxN cell lines (not shown).
Genes differentially expressed between the coxP and the 
coxN cell lines (BRB-ArrayTool, t-test, p  0.005) following 
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Figure 1 APHS effects on CRC cell growth and EPs. (A) Dose-response curves of CRC cells. Relative colony formation is the ratio of total cellular area between APHS- and 
DMSO-treated cells. The average (±SD) of three independent triplicate experiments is shown. (B) APHS-induced growth inhibition of colonies seeded at three different cell 
densities: L (240/cm2), M (1200/cm2), and H (5800/cm2). The average (±SD) of two independent experiments is shown. (C) APHS-induced expression response in coxP CRC 
cells. Differential expression in coxP relative to coxN cell lines is plotted in Venn diagrams.Biologics: Targets & Therapy 2008:2(2) 332
Humar et al
APHS treatment were computed to enrich for genes related 
to the growth inhibitory effects of APHS. Overall, 49/5429 
genes were deregulated in coxP cells relative to coxN cells 
(Table 1).
Comparison of individual coxP cell lines with coxN cells 
revealed a heterogeneous response: 81%, 79%, and 86% of 
the differentially expressed genes were speciﬁ  c to HT-29, 
CaCo-2, and HCA-7 cells, respectively. None of these genes 
Table 1 Genes differentially expressed in coxP cells relative to coxN cells
Geom mean coxP  Geom mean coxN  Ratio P/N  Identiﬁ  er  Gene symbol
0.920 1.627  0.565  AA464600  MYC
1.628 0.872  1.867  H65328  RAB11B
2.527 0.940  2.687  AA448866  DVL2
0.908 1.622  0.560  T50788  UGT2B15
0.984 0.389  2.526  AA406364  GNAI1
1.017 1.953  0.521  AA705886  MXI1
1.220 0.251  4.855  AA504832  SP110
0.903 0.459  1.969  H74265  PTPRC
1.765 0.841  2.098  AA504336  MED16
1.145 0.624  1.835  AA074446  GCHFR
1.465 0.891  1.645  W31391  TJP2
2.597 0.822  3.158  AA446120  ADM
2.019 1.016  1.988  AA857343  TAF15
1.057 0.440  2.403  AA477283  KLK11
1.549 0.712  2.176  H29475  PDK2
1.614 0.873  1.849  AA464532  THBS1
1.861 1.030  1.808  AA421701  LRRC41
1.044 0.667  1.565  AA282134  QPCT
0.748 0.307  2.433  AA455235  ALDH1A3
1.773 0.598  2.966  N74131  TFF3
0.773 1.437  0.538  R26082  ZNF354A
1.135 0.804  1.411  N55461  EPB49
0.970 1.450  0.669  AA629909  GARS
0.884 1.472  0.601  R68106  FCGR2B
0.883 1.197  0.737  AA411202  AHSA1
1.403 0.744  1.885  N50834  MVD
0.887 1.235  0.718  AA418032  ARIH1
1.204 0.829  1.453  AI209184  HIST1H2AE
1.570 1.001  1.569  N54821  IL2RG
0.930 0.278  3.344  AA458507  CSF3R
0.931 0.447  2.082  AA131693  PTHLH
0.846 1.467  0.577  W46900  CXCL1
0.837 0.319  2.629  AA291742  PML
0.835 1.367  0.611  N64508  PODXL
6.713 1.096  6.124  R72432  JAG2
1.260 0.846  1.489  AA057204  IL2RB
3.160 0.884  3.575  AA055491  TSPAN12
1.382 0.789  1.753  AA007560  PILRA
3.137 0.973  3.223  R50337  SLC19A1
0.975 1.379  0.707  AA455300  CSDA
0.964 1.299  0.742  N33236  MRPS30
2.193 0.961  2.282  AI969985  NF1
1.385 0.831  1.667  AA443090  IRF7
1.396 0.920  1.517  T67524  ZNF-like
1.149 0.592  1.941  AA418015  NEURL
1.424 0.658  2.164  AA152099  FZD4
1.129 0.494  2.287  AA670429  SGNE1
1.577 0.936  1.685  AA425437  IGSF3
0.933 1.273  0.733  AA410636  IARS
Notes: For all listed genes: permutation p  0.005.Biologics: Targets & Therapy 2008:2(2) 333
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was altered in all three cell lines simultaneously (Figure 1C, 
Table 2). These data suggest that the expression response of 
CRC cells towards COX-2 inhibition by APHS is cell line-
dependent to a large extent.
To search for biological themes in the response to COX-2 
inhibition, expression proﬁ  les were analyzed for APHS-
affected pathways using BRB-ArrayTools’ pathway com-
parison. When individual coxP cell lines were compared to 
coxN cells, seven pathways appeared altered in HT-29 cells, 
eight in CaCo-2 cells and ﬁ  ve in HCA-7 cells (Table 3).
Each pair of coxP cell lines shared only one pathway 
(Figure 1C, Table 2). Together, 15 of the 18 detected unique 
pathways were speciﬁ  c to a given cell line, consistent with 
a heterogeneous, cell line-dependent expression response of 
CRC cells towards APHS. An alternative pathway search 
was performed using PathwayAssist software, retrieving 
only one additional pathway (the retinoic acid receptor-α 
pathway) altered speciﬁ  cally in CaCo-2 cells.
QPCR was performed on selected genes to conﬁ  rm cell 
line-speciﬁ  c alterations in cancer-related pathways. Follow-
ing treatment with APHS, HT-29 cells but not other cell lines 
displayed downregulation of prion pathway components 
(Figure 2A). Likewise, CaCo-2 cells reacted with upregula-
tion of the retinoic acid receptor-α gene and several of its 
downstream targets, while HCA-7 cells showed decreased 
expression of genes related to a hypoxia/stress-induced 
pathway (Figure 2B/C). For the majority of genes assayed 
by QPCR, expression trends were similar between QPCR 
and microarray data (Table 4).
To detect low signiﬁ  cance changes that may be com-
mon to coxP cells, mean ΔZ-data from all coxP cell lines 
were combined and compared to mean ΔZ-data from coxN 
cells. Pathway analysis suggested ﬁ  ve pathways commonly 
affected by APHS in the coxP cells (Table 5).
Of those, the WNT pathway is thought to be the most 
relevant in CRC. QPCR demonstrated speciﬁ  c upregulation 
in coxP cells of WIF1, a physiological inhibitor of the path-
way (Taniguchi et al 2005), of SMAD4, which counteracts 
WNT signaling (Gregorieff and Clevers 2005), of TLE1 
(groucho), a repressor of β-catenin/Tcf-mediated transcrip-
tion (Levanon et al 1998), and no apparent change in GSKβ3, 
the kinase involved in β-catenin degradation (Gregorieff 
and Clevers 2005). The upregulation of WIF1, SMAD4 and 
TLE1 would be expected to counteract β-catenin-mediated 
transcription. MYC, a transcriptional β-catenin target and a 
growth mediator (Gregorieff and Clevers 2005), was unal-
tered in coxP cells, but was upregulated in coxN cell lines 
(Figure 2D). This is consistent with APHS-mediated inhibi-
tion of WNT pathway activation in coxP cells treated at the 
beginning of the growth phase (24 h after seeding).
Discussion
This study was performed to assess whether the response 
of CRC cells towards the CIB APHS is cell line-speciﬁ  c or 
contains common elements that may relate to the anticancer 
effects of this drug.
We ﬁ  rst established an APHS dose that signiﬁ  cantly 
affected the growth of only CRC cells expressing COX-2 and 
then applied this dose to study the drug effects by a microar-
ray approach. Cluster analysis of the expression responses 
conﬁ  rmed that the effects of APHS were speciﬁ  c for the 
coxP cells. To further select for genes likely associated with 
APHS-induced growth inhibition, only genes differentially 
expressed in coxP relative to coxN cells were included into 
analysis. The comparison of differentially expressed genes 
from each coxP cell line revealed that no gene was commonly 
affected in all three cell lines, even at the rather relaxed 
signiﬁ  cance level (p = 0.005) applied. We then performed a 
Table 2 APHS-affected genes and pathways shared between individual coxP cell lines
Common genes
HT -29/HCA-7  KLK10, AHSA1
HT -29/CaCo-2  QPCT, AKR1C2
HCA-7/CaCo-2  RPS6KA4, GCH1, GNB1, CD180, DAPK3, KIFC1, SLC19A1, SHC1, UGT2B15
Common pathways  Pathway Ida  Description  LS permutation   KS permutation 
     p-value  p-value
HT -29/HCA-7 Kegg: hsa00970  Aminoacyl-tRNA biosynthesis  0.00001  0.0004
HT -29/CaCo-2 BioCarta:   Ras-independent pathway in  0.003  0.13
  h_nkcellsPathway  NK cell-mediated cytotoxicity
HCA-7/CaCo-2 BioCarta:   Granzyme A mediated   0.003  0.1
 h_setPathway  apoptosis  pathway
Notes: aPathway accession under: http://www.genome.jp/kegg/pathway.html and http://www.biocarta.com/. Please use Pathway Id to retrieve pathways and the associated 
genes.Biologics: Targets & Therapy 2008:2(2) 334
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search for pathways altered by APHS treatment. Again, none 
of the altered pathways was affected in all three cell lines 
simultaneously. Together, the array analysis suggested that 
APHS induces a heterogeneous expression response that is 
dependent on the studied CRC cell line.
Since microarray analysis can produce false results and 
is of limited sensitivity at the single gene level, we used the 
array output as a basis from which to investigate the APHS-
induced expression response of CRC cells by QPCR. There-
fore, it is important to stress that the biological interpretation 
of our ﬁ  ndings is based on our QPCR-derived data.
Our QPCR results conﬁ  rmed that APHS can affect path-
ways in a cell-line speciﬁ  c manner. QPCR indicated cell line-
speciﬁ  c deregulation of genes from selected cancer-related 
pathways in individual coxP cell lines. The corresponding 
putative, underlying pathways and their biological effects are 
depicted in Figure 2. The pathway-associated gene alterations 
might represent mechanisms that contribute to the anticancer 
activity of CIBs. In HCA-7 cells for example, the genes 
encoding the prion protein and its receptor were downregu-
lated by APHS. Both PRNP and LAMR1 are known to be 
overexpressed in gastrointestinal disease (Cioce et al 1991; 
Liang et al 2006), consistent with a tumor-inhibiting APHS 
effect. Likewise, the speciﬁ  c upregulation of the retinoic acid 
(RA) receptor-α gene and several RA-inducible genes in 
CaCo-2 cells may be tumor-suppressive (Altucci et al 2007) 
and is of potential interest, as it suggests COX-2 inhibition 
might sensitize a subset of CRCs to the antineoplastic effects 
of RA. A possible explanation for this cell-speciﬁ  city may 
lie in the different differentiation level of investigated cell 
lines. Clustering of the expression proﬁ  les of vehicle-treated 
cells with a set of genes involved in colonic differentiation 
indicated HT-29 cells to be least and CaCo-2 cells to be most 
differentiated (not shown). In line with this, PRNP expres-
sion appears to correlate with poor differentiation in gastric 
cancer (Liang et al 2006), while RA-receptor-α is a known 
differentiation inducer (Nadauld et al 2004). Together, these 
data suggest that COX-2 inhibition induces a cell line-speciﬁ  c 
expression response that is dependent on factors such as the 
cellular differentiation level.
In an attempt to detect low-signiﬁ  cance changes which 
might be part of a common expression response towards 
APHS, we compared combined array data from all coxP 
cell lines with data from the coxN cells. Of the identiﬁ  ed 
pathways, only the WNT pathway is both an established 
cancer pathway and known to be of direct relevance for 
CRC (Gregorieff and Clevers 2005). Conﬁ  rmation by QPCR 
indicated small expression alteration that were common to 
all coxP cells and consistent with a downregulation of WNT 
signaling. These transcriptional alterations may not be sig-
niﬁ  cant on a single gene-level, explaining why they were 
detected by the less sensitive array approach only when cell 
lines were combined. However, their biologically meaningful 
direction and their simultaneous presence in all coxP cells 
is biologically signiﬁ  cant. The WNT pathway as a possible 
APHS-target is an interesting ﬁ  nding, as the majority of CRCs 
Table 3 Unique pathways altered by APHS in individual coxP cell lines
Pathway Ida  Description  LS permutation   KS permutation
   p-value  p-value
HT -29
Kegg: hsa00190  Oxidative phosphorylation  0.0002  0.009
BioCarta: h_prionPathway  Prion pathway  0.0008  0.009
BioCarta: h_eifPathway  Eukaryotic protein translation  0.002  0.0004
BioCarta: h_hcmvPathway  Cytomegalovirus and Map kinase pathways  0.004  0.22
Kegg: hsa00100  Sterol biosynthesis  0.02  0.004
HCA-7    
Kegg: hsa00010  Glycolysis, gluconeogenesis  0.002  0.003
BioCarta: h_ecmPathway  Erk and PI-3 kinase in collagen binding  0.004  0.043
BioCarta: h_p53hypoxiaPathway  Hypoxia and p53 in the cardiovascular system  0.03  0.003
CaCo-2b    
BioCarta: h_erkPathway  Erk1/Erk2 Mapk signaling  0.00002  0.014
BioCarta: h_igf1rPathway  Antiapoptotic pathways from Igf-1 receptor signaling  0.001  0.002
BioCarta: h_il2Pathway  Il-2 signaling pathway  0.002  0.053
BioCarta: h_biopeptidesPathway  Bioactive peptide induced aignaling pathway  0.003  0.04
BioCarta: h_barr-mapkPathway  Arrestins and activation of Map kinases  0.003  0.22
BioCarta: h_her2Pathway  Erbb2 in signal transduction and oncology  0.004  0.06
Notes: aPathway accession under: http://www.genome.jp/kegg/pathway.html and http://www.biocarta.com/. Please use Pathway Id to retrieve pathways and the associated 
genes; b the RARA pathway was detected using PathwayAssist software and is not listed on this table.Biologics: Targets & Therapy 2008:2(2) 335
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harbor bi-allelic mutations in the APC tumor suppressor, 
leading to activation of the WNT pathway via stabilization 
of β-catenin. Importantly, the cell lines we investigated all 
have an activated WNT pathway, either due to APC muta-
tion (HT-29, SW480/620, CaCo-2) or manifested as elevated 
transcriptional β-catenin activity (HCA-7) (Mariadason et al 
2001; Huang and Guo 2006). Constitutive β-catenin activation 
is thought to be the key event in colorectal carcinogenesis, 
because it induces transcription of genes involved in self-
renewal and malignant transformation (Gregorieff and Clevers 
2005). Of those, MYC appears to be the most crucial target, as 
its conditional deletion alone is sufﬁ  cient to revert the WNT 
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Figure 2 Expression by QPCR of selected genes from differentially expressed pathways. The charts show fold induction (±SD from triplicates) by APHS relative to DMSO 
treatment. The diagrams propose pathways that may underlie the observed expression changes. (A) Chronic inﬂ  ammation mediated via COX-2 is associated with increased 
levels of prion protein. COX-2 inhibition may thus be related to reduced PRNP expression following APHS treatment. Prion protein binds to the laminin receptor 1 and can 
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pathway induced phenotype in vivo (Muncan et al 2006; van 
de Wetering et al 2002). The inhibition of MYC upregulation 
in the coxP cells following treatment may thus be related to the 
observed APHS-mediated growth inhibition. Notably, PGE2 
has recently been shown to stimulate β-catenin-mediated 
transcription (Fujino et al 2002; Castellone et al 2005; Shao 
et al 2005). Blocked PGE2 production due to APHS treatment 
may therefore cause WNT signaling repression. Our results 
suggest this inhibition also occurs at the transcriptional level 
of WNT pathway related genes. Whether these effects are 
direct and common to all CIBs remains to be determined. 
Clearly, pathways other than WNT signaling may be part
of a common response to COX-2 inhibition. Some of these 
pathways may be included in Table 2, however, their direct 
role in CRC cells has not been demonstrated yet. Alternatively, 
genes affected by APHS could be involved in pathways not 
represented in the searched databases or not contained in the 
used arrays. Also, pathways that are regulated mainly on the 
post-transcriptional level would remain undetected by our 
approach. However, the observation of similar expression 
changes in three unrelated coxP CRC cell lines suggests the 
WNT pathway may be a universal target of COX-2 inhibition 
by APHS. In support of our results, increasing evidence indi-
cates a negative effect of various NSAIDs on WNT signaling 
both in vitro and in vivo (Brown et al 2001; Kishimoto et al 
2002; Williams et al 2003; Boon et al 2004; Maier et al 2005; 
Roy et al 2005; Kapitanovic et al 2006; Rao et al 2006).
In summary, our results indicate the cell line-dependent 
nature of expression changes induced by COX-2 inhibition 
and provide one explanation for the divergent molecular 
CIB targets identiﬁ  ed to date. Likely, drug-speciﬁ  c effects 
will add to the heterogeneity of CRC cell line responses 
towards NSAIDs. However, APHS-mediated gene expres-
sion changes related to the WNT pathway could be identiﬁ  ed 
that were shared by all COX-2 positive cell lines. These ﬁ  nd-
ings, together with the other reports on PGE2 and the WNT 
pathway, suggest a possible common mechanism underlying 
the effects COX-2 inhibition has on CRC growth. Given 
that WNT pathway activation is a very early event and has 
pleiotropic effects in colonic carcinogenesis, CIB-induced 
suppression of WNT activity could not only explain the 
preventive properties of NSAIDs, but also the variety of 
processes affected by these inhibitors. Thus, the WNT path-
way is a promising candidate to explain some of the basic 
anticancer properties of COX-2 inhibitors.
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